Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin
ConclusionsDalbavancin inoculum effect is a major issue in bacterial infections with high bacterial loads and the combination of DAL plus single dose of DAP showed promise in eradicating resistantS. aureus strains at high inoculums. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 1, 2023 Category: Infectious Diseases Source Type: research
Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study
ConclusionRemdesivir generally does not increase the incidence of rapid clinical improvement in hospitalised patients with COVID-19, but it might have an effect in patients with short duration of symptoms and limited signs of systemic inflammation. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 1, 2023 Category: Infectious Diseases Source Type: research
Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study
ConclusionsThis trial did not meet the primary efficacy endpoints, yet reparixin showed a trend toward limiting disease progression as an add-on therapy in COVID-19 severe pneumonia and was well tolerated.Trial RegistrationClinicalTrials.gov: NCT04878055, EudraCT: 2020-005919-51.Graphical Abstract (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - October 1, 2023 Category: Infectious Diseases Source Type: research
Distinguishing the Vaccine Effectiveness of Inactivated BBIBP-CorV Vaccine Booster Against the Susceptibility, Infectiousness, and Transmission of Omicron Stains: A Retrospective Cohort Study in Urumqi, China
ConclusionBBIBP-CorV vaccine booster was associated with mild to moderate levels of protection against Omicron susceptibility, infectiousness, and transmission. Real-world assessment of protective performance of COVID-19 vaccines against the risk of Omicron strains is continuously needed, and may provide information that helps vaccination strategy. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 28, 2023 Category: Infectious Diseases Source Type: research
Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea
ConclusionsThese findings provide insights to the epidemiology, clinical burden, treatment patterns, and healthcare costs of CHB and HBV/HDV co-infection in South Korea. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 28, 2023 Category: Infectious Diseases Source Type: research
Distinguishing the Vaccine Effectiveness of Inactivated BBIBP-CorV Vaccine Booster Against the Susceptibility, Infectiousness, and Transmission of Omicron Stains: A Retrospective Cohort Study in Urumqi, China
ConclusionBBIBP-CorV vaccine booster was associated with mild to moderate levels of protection against Omicron susceptibility, infectiousness, and transmission. Real-world assessment of protective performance of COVID-19 vaccines against the risk of Omicron strains is continuously needed, and may provide information that helps vaccination strategy. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 28, 2023 Category: Infectious Diseases Source Type: research
Real-World Epidemiology, Treatment Patterns, and Disease Burden of Chronic Hepatitis B and HDV Co-Infection in South Korea
ConclusionsThese findings provide insights to the epidemiology, clinical burden, treatment patterns, and healthcare costs of CHB and HBV/HDV co-infection in South Korea. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 28, 2023 Category: Infectious Diseases Source Type: research
Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older
ConclusionsThe benefit-risk profile for MenACYW-TT showed favorable seroresponse and seroprotection in individuals aged ≥ 2 years and no difference in risk criteria between MenACYW-TT and MCV4s. MenACYW-TT may provide an alternative to the standard-of-care for meningococcal disease prevention in those aged ≥ 12 months. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 27, 2023 Category: Infectious Diseases Source Type: research
Correction to: Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies
(Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 27, 2023 Category: Infectious Diseases Source Type: research
Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older
ConclusionsThe benefit-risk profile for MenACYW-TT showed favorable seroresponse and seroprotection in individuals aged ≥ 2 years and no difference in risk criteria between MenACYW-TT and MCV4s. MenACYW-TT may provide an alternative to the standard-of-care for meningococcal disease prevention in those aged ≥ 12 months. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 27, 2023 Category: Infectious Diseases Source Type: research
Correction to: Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies
(Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 27, 2023 Category: Infectious Diseases Source Type: research
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
ConclusionsAZD7442 was well tolerated and reduced hospitalization and mortality through 6 months, and symptom burden through 29 days, in outpatients with mild-to-moderate COVID-19.Clinical Trial RegistrationClinicaltrials.gov, NCT04723394. (https://beta.clinicaltrials.gov/study/NCT04723394).Graphical Abstract (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 26, 2023 Category: Infectious Diseases Source Type: research
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
ConclusionThrough ~5 years, fostemsavir + OBT demonstrated durable virologic and immunologic responses with no new safety concerns between Weeks 96 and 240, supporting this regimen as a key therapeutic option for HTE people with multidrug-resistant HIV-1.Trial registrationClinicalTrials.gov, NCT02362503. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 26, 2023 Category: Infectious Diseases Source Type: research
A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category
ConclusionHigh-dose daptomycin was not associated with increased laboratory abnormalities or adverse drug reactions compared to standard-dose daptomycin. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 26, 2023 Category: Infectious Diseases Source Type: research
Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study
This study will help characterize the risk –benefit profile of gepotidacin for treating uncomplicated urogenital gonorrhea. Gepotidacin is an important potential treatment for gonorrhea to help address the urgent unmet need of multidrug resistance and the increasingly limited number of oral treatment options.Trial RegistrationClinicalTrials.gov identifier, NCT04010539. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - September 26, 2023 Category: Infectious Diseases Source Type: research
